- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03373045
Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE)
The CHRONICLE Study: A Longitudinal Prospective Observational Study of the Characteristics, Treatment Patterns and Health Outcomes of Individuals With Severe Asthma in the United States
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: AstraZeneca Clinical Study Information Center
- Phone Number: 1-877-240-9479
- Email: information.center@astrazeneca.com
Study Locations
-
-
-
Guaynabo, Puerto Rico, 00968
- Terminated
- Research Site
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35209
- Recruiting
- Research Site
-
Birmingham, Alabama, United States, 35294
- Recruiting
- Research Site
-
Hoover, Alabama, United States, 35244
- Recruiting
- Research Site
-
-
Arizona
-
Gilbert, Arizona, United States, 85234
- Terminated
- Research Site
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- Recruiting
- Research Site
-
-
California
-
Bakersfield, California, United States, 93301
- Recruiting
- Research Site
-
Los Angeles, California, United States, 90025
- Recruiting
- Research Site
-
Redondo Beach, California, United States, 90277
- Recruiting
- Research Site
-
Riverside, California, United States, 92506
- Recruiting
- Research Site
-
Roseville, California, United States, 95661
- Terminated
- Research Site
-
Sacramento, California, United States, 95819
- Terminated
- Research Site
-
Studio City, California, United States, 91607
- Recruiting
- Research Site
-
Ventura, California, United States, 93003
- Recruiting
- Research Site
-
Westminster, California, United States, 92683
- Recruiting
- Research Site
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Recruiting
- Research Site
-
-
Connecticut
-
Danbury, Connecticut, United States, 06810
- Recruiting
- Research Site
-
New Haven, Connecticut, United States, 06510
- Recruiting
- Research Site
-
Waterbury, Connecticut, United States, 06708
- Terminated
- Research Site
-
-
Florida
-
Clearwater, Florida, United States, 33765
- Recruiting
- Research Site
-
Coral Gables, Florida, United States, 33134
- Recruiting
- Research Site
-
Gainesville, Florida, United States, 32608
- Recruiting
- Research Site
-
Jacksonville, Florida, United States, 32204
- Recruiting
- Research Site
-
Kissimmee, Florida, United States, 34759
- Terminated
- Research Site
-
Lake Mary, Florida, United States, 32746
- Recruiting
- Research Site
-
Miami, Florida, United States, 33175
- Terminated
- Research Site
-
Miami, Florida, United States, 33176
- Terminated
- Research Site
-
Miami Beach, Florida, United States, 33140
- Terminated
- Research Site
-
Plantation, Florida, United States, 33317
- Terminated
- Research Site
-
Saint Petersburg, Florida, United States, 33704
- Recruiting
- Research Site
-
Tallahassee, Florida, United States, 32308
- Recruiting
- Research Site
-
Tampa, Florida, United States, 33613
- Recruiting
- Research Site
-
-
Georgia
-
Albany, Georgia, United States, 31707
- Terminated
- Research Site
-
Decatur, Georgia, United States, 30033
- Recruiting
- Research Site
-
Gainesville, Georgia, United States, 30501
- Terminated
- Research Site
-
-
Idaho
-
Boise, Idaho, United States, 83706
- Recruiting
- Research Site
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Recruiting
- Research Site
-
Chicago, Illinois, United States, 60637
- Withdrawn
- Research Site
-
Chicago, Illinois, United States, 60612
- Recruiting
- Research Site
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- Recruiting
- Research Site
-
West Des Moines, Iowa, United States, 50266
- Recruiting
- Research Site
-
-
Kansas
-
Overland Park, Kansas, United States, 66210
- Recruiting
- Research Site
-
-
Kentucky
-
Georgetown, Kentucky, United States, 40324
- Recruiting
- Research Site
-
Lexington, Kentucky, United States, 40509
- Recruiting
- Research Site
-
Lexington, Kentucky, United States, 40503
- Terminated
- Research Site
-
Louisville, Kentucky, United States, 40215
- Recruiting
- Research Site
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70112
- Recruiting
- Research Site
-
New Orleans, Louisiana, United States, 70127
- Recruiting
- Research Site
-
Shreveport, Louisiana, United States, 71106
- Recruiting
- Research Site
-
-
Maryland
-
Rockville, Maryland, United States, 20852
- Recruiting
- Research Site
-
Silver Spring, Maryland, United States, 20902
- Recruiting
- Research Site
-
-
Massachusetts
-
Burlington, Massachusetts, United States, 01805
- Recruiting
- Research Site
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48106
- Recruiting
- Research Site
-
Ann Arbor, Michigan, United States, 48109
- Terminated
- Research Site
-
Clinton Township, Michigan, United States, 48038
- Recruiting
- Research Site
-
Flint, Michigan, United States, 48532
- Withdrawn
- Research Site
-
Hamtramck, Michigan, United States, 48211
- Terminated
- Research Site
-
Wyoming, Michigan, United States, 49519
- Recruiting
- Research Site
-
-
Minnesota
-
Maplewood, Minnesota, United States, 55109
- Recruiting
- Research Site
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Recruiting
- Research Site
-
-
Nebraska
-
Bellevue, Nebraska, United States, 68123
- Withdrawn
- Research Site
-
Lincoln, Nebraska, United States, 68505
- Terminated
- Research Site
-
Omaha, Nebraska, United States, 68124
- Recruiting
- Research Site
-
Omaha, Nebraska, United States, 68105
- Recruiting
- Research Site
-
Omaha, Nebraska, United States, 68114
- Recruiting
- Research Site
-
-
New Jersey
-
Brick, New Jersey, United States, 08724
- Recruiting
- Research Site
-
Marlton, New Jersey, United States, 08053
- Recruiting
- Research Site
-
New Brunswick, New Jersey, United States, 08901
- Recruiting
- Research Site
-
North Bergen, New Jersey, United States, 07047
- Recruiting
- Research Site
-
Northfield, New Jersey, United States, 08225
- Recruiting
- Research Site
-
Toms River, New Jersey, United States, 08755
- Recruiting
- Research Site
-
Toms River, New Jersey, United States, 08755
- Terminated
- Research Site
-
Verona, New Jersey, United States, 07044
- Terminated
- Research Site
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87109
- Terminated
- Research Site
-
-
New York
-
Bayside, New York, United States, 11361
- Terminated
- Research Site
-
Bronx, New York, United States, 10461
- Recruiting
- Research Site
-
Bronx, New York, United States, 10459
- Recruiting
- Research Site
-
Bronx, New York, United States, 10458
- Recruiting
- Research Site
-
Bronx, New York, United States, 10465
- Recruiting
- Research Site
-
Brooklyn, New York, United States, 11236
- Recruiting
- Research Site
-
Brooklyn, New York, United States, 11230
- Terminated
- Research Site
-
Corning, New York, United States, 14830
- Terminated
- Research Site
-
Great Neck, New York, United States, 11023
- Terminated
- Research Site
-
Mineola, New York, United States, 11501
- Recruiting
- Research Site
-
New Hyde Park, New York, United States, 11042
- Recruiting
- Research Site
-
New Paltz, New York, United States, 12561
- Terminated
- Research Site
-
New York, New York, United States, 10022
- Recruiting
- Research Site
-
Rochester, New York, United States, 14642
- Recruiting
- Research Site
-
Rockville Centre, New York, United States, 11570
- Terminated
- Research Site
-
Staten Island, New York, United States, 10305
- Terminated
- Research Site
-
Valhalla, New York, United States, 10595
- Recruiting
- Research Site
-
-
North Carolina
-
Asheville, North Carolina, United States, 28801
- Recruiting
- Research Site
-
Chapel Hill, North Carolina, United States, 27599
- Recruiting
- Research Site
-
Charlotte, North Carolina, United States, 28204
- Recruiting
- Research Site
-
Durham, North Carolina, United States, 27701
- Recruiting
- Research Site
-
Fayetteville, North Carolina, United States, 28304
- Terminated
- Research Site
-
Greenville, North Carolina, United States, 27834
- Recruiting
- Research Site
-
Winston-Salem, North Carolina, United States, 27157
- Recruiting
- Research Site
-
-
Ohio
-
Toledo, Ohio, United States, 43617
- Recruiting
- Research Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73120
- Recruiting
- Research Site
-
-
Oregon
-
Corvallis, Oregon, United States, 97330
- Terminated
- Research Site
-
Portland, Oregon, United States, 97225
- Recruiting
- Research Site
-
Portland, Oregon, United States, 97220
- Recruiting
- Research Site
-
-
Pennsylvania
-
Altoona, Pennsylvania, United States, 16601
- Recruiting
- Research Site
-
DuBois, Pennsylvania, United States, 15801
- Recruiting
- Research Site
-
Harrisburg, Pennsylvania, United States, 17109
- Terminated
- Research Site
-
Philadelphia, Pennsylvania, United States, 19107
- Recruiting
- Research Site
-
Pittsburgh, Pennsylvania, United States, 15241
- Recruiting
- Research Site
-
Sayre, Pennsylvania, United States, 18840
- Recruiting
- Research Site
-
Yardley, Pennsylvania, United States, 19067
- Recruiting
- Research Site
-
-
Rhode Island
-
Lincoln, Rhode Island, United States, 02865
- Recruiting
- Research Site
-
-
South Carolina
-
Clinton, South Carolina, United States, 29325
- Terminated
- Research Site
-
Greenville, South Carolina, United States, 29607
- Recruiting
- Research Site
-
Mount Pleasant, South Carolina, United States, 29464
- Terminated
- Research Site
-
Rock Hill, South Carolina, United States, 29732
- Recruiting
- Research Site
-
-
Tennessee
-
Hendersonville, Tennessee, United States, 37075
- Recruiting
- Research Site
-
-
Texas
-
Aransas Pass, Texas, United States, 78336
- Terminated
- Research Site
-
Dallas, Texas, United States, 75246
- Recruiting
- Research Site
-
Denison, Texas, United States, 75020
- Recruiting
- Research Site
-
Duncanville, Texas, United States, 75116
- Terminated
- Research Site
-
Fort Worth, Texas, United States, 76107
- Recruiting
- Research Site
-
Houston, Texas, United States, 77030
- Recruiting
- Research Site
-
Houston, Texas, United States, 77043
- Terminated
- Research Site
-
Houston, Texas, United States, 77079
- Recruiting
- Research Site
-
Kingwood, Texas, United States, 77339
- Recruiting
- Research Site
-
Live Oak, Texas, United States, 78233
- Terminated
- Research Site
-
McKinney, Texas, United States, 75069
- Terminated
- Research Site
-
San Antonio, Texas, United States, 78251
- Recruiting
- Research Site
-
Sugar Land, Texas, United States, 77478
- Recruiting
- Research Site
-
-
Utah
-
Murray, Utah, United States, 84107
- Recruiting
- Research Site
-
-
Virginia
-
Lynchburg, Virginia, United States, 24501
- Recruiting
- Research Site
-
Newport News, Virginia, United States, 23606
- Recruiting
- Research Site
-
Norfolk, Virginia, United States, 23507
- Terminated
- Research Site
-
Richmond, Virginia, United States, 23229
- Terminated
- Research Site
-
Richmond, Virginia, United States, 23298
- Recruiting
- Research Site
-
-
Washington
-
Tacoma, Washington, United States, 98405
- Recruiting
- Research Site
-
Vancouver, Washington, United States, 98664
- Recruiting
- Research Site
-
-
Wisconsin
-
Greenfield, Wisconsin, United States, 53228
- Recruiting
- Research Site
-
Onalaska, Wisconsin, United States, 54650
- Recruiting
- Research Site
-
Wausau, Wisconsin, United States, 54401
- Terminated
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
1. Individuals with a diagnosis of severe asthma for at least 12 months prior to enrollment and confirmed by the Investigator not to be due to alternative diagnoses.
2. Currently receiving care from specialist physicians (eg, pulmonologists and or allergists) at the Investigator's or sub-investigator's site.
3. 18 years of age and older. 4. Meeting at least one of the following three criteria (a, b, or c):
a. Uncontrolled asthma while receiving high-dose ICS with additional controllers.
i. Uncontrolled is defined by meeting at least one of the following (as outlined by ATS/ERS [American Thoracic Society/European Respiratory Society] guidelines):
- Poor symptom control: Asthma Control Questionnaire consistently ≥1.5, ACT <20 (or "not well controlled" by NAEPP [National Asthma Education and Prevention Program]/Global Initiative for Asthma guidelines).
- Frequent severe exacerbations: two or more bursts of systemic corticosteroids (≥3 days each) in the previous 12 months.
- Serious exacerbations: at least one hospitalization, intensive care unit stay or mechanical ventilation in the previous 12 months.
- Airflow limitation: after appropriate bronchodilator withhold FEV1 <80% predicted (in the face of reduced FEV1/FVC defined as less than the lower limit of normal).
ii. For the purposes of this study, high-dose ICS will be defined as
1. ICS at a cumulative dose of >500 μg fluticasone propionate equivalents daily as defined in Appendix A, or 2. Highest labeled dose of a combination of ICS/LABA. b. Current use of a Food and Drug Administration (FDA)-approved monoclonal antibody agent for treatment of severe asthma (use is not primarily for an alternative condition).
c. Use of systemic corticosteroids or other systemic immunosuppressants (any dose level) for approximately 50% or more of the prior 12 months for treatment of severe asthma (use is not primarily for an alternative condition).
Exclusion Criteria
- Not willing and able to sign written informed consent. Consent can be obtained from having a responsible, legally authorized representative acting on patient's behalf.
- Not fluent in English or Spanish.
- Inability to complete study follow-up or web-based PROs. If the patient does not have email or web access, minimal assistance from others to access the web-based PRO is permitted (ie receiving the email and/or assisting patient in navigating to the web page); PROs must be completed by the patient.
Received an investigational therapy for asthma, allergy, atopic disease, or eosinophilic disease as part of a clinical trial during the 6 months prior to enrollment.
- Once enrolled in the CHRONICLE Study, patients can enroll in trials of investigational therapies (as well as other non-interventional studies) as long as they continue to complete study follow-up. If a patient enrolls in a trial of an investigational therapy, the identity (National Clinical Trial [NCT] number) of the study and dates of the first and last investigational therapy administrations will be collected. If a patient receives blinded therapy in a trial, the Investigator will request the identity of that therapy at trial conclusion so that treatment information collected for the current study may be updated accordingly.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
Cohort of US adults with severe asthma
To describe patient characteristics, treatment patterns, and health outcomes among a large, geographically diverse cohort of US adults with severe asthma who are not controlled on high-dose ICS with additional controllers and/or require chronic systemic corticosteroid or monoclonal antibody therapy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Healthcare utilization- hospitalizations, clinic Visits, and asthma exacerbations
Time Frame: At baseline, every 6 months, through study completion, assessed up to 7 years.
|
Longitudinal changes of Healthcare utilization will be measured using directly collected information from medical, hospital, and pharmacy records to provide a supplementary comprehensive assessment of each patient's healthcare utilization during the study period.
|
At baseline, every 6 months, through study completion, assessed up to 7 years.
|
Asthma treatment
Time Frame: At baseline, every 6 months, through study completion, assessed up to 7 years.
|
Asthma medications with dose and start/stop dates including all FDA-approved and standard of care treatments for asthma will be assessed.
Longitudinal changes in asthma treatment will also be assessed.
|
At baseline, every 6 months, through study completion, assessed up to 7 years.
|
Treatment adherence
Time Frame: At baseline, every 1 month, through study completion, assessed up to 7 years.
|
Extraction of electronic medical, hospital, and pharmacy records will take place at study close and potentially at interim time points to provide a supplementary assessment of each patient's healthcare resource utilization.
Longitudinal changes in patient reported treatment adherence will also be assessed.
|
At baseline, every 1 month, through study completion, assessed up to 7 years.
|
Asthma control test (ACT)
Time Frame: Change from baseline, every 1 month, through study completion, assessed up to 4 years.
|
Patient-reported asthma symptoms and control will be collected via the ACT questionnaire; a 5 item, self-administered survey that is designed to help the patient describe their asthma and how it affects their daily activities. ACT questionnaire is a 5-point scale (for symptoms and activities: 1=all the time to 5= not at all; for asthma control rating: 1=not controlled at all to 5=completely controlled). In 2022, the ACT survey will be removed, and only the AIRQ will be solicited monthly. |
Change from baseline, every 1 month, through study completion, assessed up to 4 years.
|
Patient-reported asthma exacerbations
Time Frame: Change from baseline, every 1 month, through study completion, assessed up to 4 years.
|
Asthma exacerbations, the primary analytical definition will be worsening of asthma that leads to any of the following: Use of systemic corticosteroids (or a temporary increase in a stable corticosteroid background dose) for at least 3 days; a single depo-injectable dose of corticosteroids will be considered equivalent to a 3-day course of systemic corticosteroids. An emergency department or urgent care visit (defined as evaluation and treatment for <24 hours in an emergency department or urgent care center) due to asthma that required systemic corticosteroids. An inpatient hospitalization (defined as admission to an inpatient facility and/or evaluation and treatment in a healthcare facility for ≥24 hours) due to asthma. In 2022, the asthma exacerbations survey will be removed, and only the AIRQ will be solicited monthly. |
Change from baseline, every 1 month, through study completion, assessed up to 4 years.
|
Asthma Impairment and Risk Questionnaire (AIRQ)
Time Frame: At baseline, every 1 month, through study completion, assessed up to 4 years
|
AIRQ is a 10-item, equally weighted, yes/no composite asthma control questionnaire that includes 7 impairment and 3 risk items.
AIRQ scores range from 0 to 10, with lower scores representing better controlled asthma.
|
At baseline, every 1 month, through study completion, assessed up to 4 years
|
Work Productivity and Activity Impairment Asthma questionnaire (WPAI-Asthma)
Time Frame: At baseline, every 3 months, through study completion, assessed up to 7 years.
|
Patient-reported productivity impairment assessment including work productivity, activity impairment, and disability will be collected via the WPAI-Asthma.
Information will only be collected from procedures that are part of the patient's routine clinical care.
WPAI Asthma questionnaire is calculated from 0 to 10 score (0 indicates-Asthma had no effect on my work/ daily activities and 10 indicates Asthma completely prevented me from working score/ doing my daily activities).
|
At baseline, every 3 months, through study completion, assessed up to 7 years.
|
St. George's Respiratory Questionnaire (SGRQ)
Time Frame: At baseline, every 6 months, through study completion, assessed up to 7 years.
|
Patient-reported assessment of asthma quality of life will be collected via the SGRQ. SGRQ, a disease specific health-related quality of life measure developed for both asthma and chronic obstructive pulmonary disease (COPD) patients. The SGRQ has 50 items and scores are calculated for 3 domains (symptoms, activity, and impact [psychosocial]) as well as total score. Symptoms - this component is concerned with the effect of respiratory symptoms, their frequency and severity. Impacts (psychosocial) - covers a range of aspects concerned with social functioning and psychological disturbances resulting from respiratory disease Activity - concerned with activities that cause or are limited by breathlessness. Total score summarizes the impact of the disease on overall health status. The score is expressed as a percentage of overall impairment, where 100 represents worst possible health status and 0 indicates best possible health status. |
At baseline, every 6 months, through study completion, assessed up to 7 years.
|
Global evaluation of treatment effectiveness (GETE)
Time Frame: At baseline, every 6 months, through study completion, assessed maximum up to 7 years.
|
Patient evaluation of asthma treatment effectiveness will be measured using GETE; a simple measure of perceived treatment effectiveness.
The patient will grade the overall treatment effectiveness using the following criteria: excellent (complete control of asthma); good (marked improvement of asthma); moderate (discernible, but limited improvement in asthma); poor (no appreciable change in asthma); or worsening (of asthma).
|
At baseline, every 6 months, through study completion, assessed maximum up to 7 years.
|
Number of Participants With Adverse Events associated with corticosteroid therapy
Time Frame: At baseline, every 6 months, through study completion, assessed up to 7 years.
|
Frequency of relevant medical events such as weight gain (change in BMI), hypertension, dyslipidemia, pneumonia, bone densitometry results, osteoporosis / osteopenia, hip and spinal fractures, avascular necrosis, cataract, glaucoma, diabetes mellitus, cardiovascular disease, Cushing's syndrome, adrenal insufficiency, peptic ulcer disease, myopathy, pseudotumor cerebri, mood disturbance, and insomnia or sleep disturbance.
|
At baseline, every 6 months, through study completion, assessed up to 7 years.
|
Relevant respiratory medical events
Time Frame: At baseline, every 6 months, through study completion,assessed up to 7 years.
|
Frequency of relevant respiratory medical events such as pneumonia, pleural effusion, chronic bronchitis, allergic rhinitis.
|
At baseline, every 6 months, through study completion,assessed up to 7 years.
|
Respiratory comorbidities
Time Frame: At baseline, every 6 months, through study completion, assessed up to 7 years.
|
Prevalence of respiratory comorbidities such as chronic obstructive pulmonary disease (COPD), bronchiectasis, alpha-1 anti-trypsin deficiency, Churg- Strauss syndrome (eosinophilic granulomatosis with polyangiitis [EGPA]), airway stenosis, cystic fibrosis, allergic bronchopulmonary aspergillosis,chronic eosinophilic pneumonia, bronchiolitis obliterans, immunodeficiency, primary ciliary dyskinesia, atelectasis, arterial hypertension, pulmonary hypertension, neuromuscular disease, allergic rhinitis, chronic rhinosinusitis, and pulmonary embolism.
|
At baseline, every 6 months, through study completion, assessed up to 7 years.
|
Non-respiratory comorbidities
Time Frame: At baseline, every 6 months, through study completion, assessed up to 7 years.
|
Prevalence of non-respiratory comorbidities such as diabetes, thyroid disease, cardiac disease, etc.
|
At baseline, every 6 months, through study completion, assessed up to 7 years.
|
Events of special interest
Time Frame: At baseline, every 6 months, through study completion, assessed up to 7 years.
|
Frequency of special interest events including new onset malignancy, severe infection, anaphylaxis, or mortality.
|
At baseline, every 6 months, through study completion, assessed up to 7 years.
|
Complete blood count with differential including blood eosinophil count.
Time Frame: Change from baseline, every 6 months, through study completion, assessed up to 7 years.
|
To assess complete blood count with differential including blood eosinophil count as a variable for asthma evaluation.
|
Change from baseline, every 6 months, through study completion, assessed up to 7 years.
|
Total immunoglobulin E (IgE)
Time Frame: Change from baseline, every 6 months, through study completion, assessed up to 7 years.
|
To assess total IgE as a variable for asthma evaluation.
|
Change from baseline, every 6 months, through study completion, assessed up to 7 years.
|
Radiographic changes in asthma evaluation.
Time Frame: Change from baseline, every 6 months, through study completion, assessed up to 7 years.
|
Radiographic changes in asthma evaluation included chest X-rays (dates, views, description of major chest findings), Chest computed tomography scan (dates, high resolution (yes/no), intravenous contrast (yes/no), description of major findings).
Radiographic asthma evaluation conducted as part of routine care.
|
Change from baseline, every 6 months, through study completion, assessed up to 7 years.
|
Forced Vital Capacity (FVC)
Time Frame: Change from baseline, every 6 months, through study completion, assessed up to 7 years.
|
FEV1 (liters and % predicted) will be assessed as a variable for asthma evaluation.
|
Change from baseline, every 6 months, through study completion, assessed up to 7 years.
|
Forced Expiratory Volume in 1 second (FEV1)
Time Frame: Change from baseline, every 6 months, through study completion, assessed up to 7 years.
|
FEV1 (liters and % predicted) will be assessed as a variable for asthma evaluation.
|
Change from baseline, every 6 months, through study completion, assessed up to 7 years.
|
Fractional exhaled nitric oxide (FENO)
Time Frame: Change from baseline, every 6 months, through study completion, assessed up to 7 years.
|
To assess FENO as a variable for asthma evaluation.
|
Change from baseline, every 6 months, through study completion, assessed up to 7 years.
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Panettieri RA Jr, Ledford DK, Chipps BE, Soong W, Lugogo N, Carr W, Mohan A, Carstens D, Genofre E, Trudo F, Ambrose CS. Biologic use and outcomes among adults with severe asthma treated by US subspecialists. Ann Allergy Asthma Immunol. 2022 Oct;129(4):467-474.e3. doi: 10.1016/j.anai.2022.06.012. Epub 2022 Jun 19.
- Panettieri RA Jr, Chipps BE, Moore WC, Soong W, Carr WW, Kreindler JL, O'Quinn S, Trudo F, Ambrose CS. Differing perceptions of asthma control and treatment effectiveness by patients with severe asthma and treating subspecialists in the United States. J Asthma. 2022 Sep;59(9):1859-1868. doi: 10.1080/02770903.2021.1963766. Epub 2021 Nov 5.
- Trevor J, Lugogo N, Carr W, Moore WC, Soong W, Panettieri RA Jr,, Desai P, Trudo F, Ambrose CS. Severe asthma exacerbations in the United States:: Incidence, characteristics, predictors, and effects of biologic treatments. Ann Allergy Asthma Immunol. 2021 Nov;127(5):579-587.e1. doi: 10.1016/j.anai.2021.07.010. Epub 2021 Jul 15.
- Soong W, Chipps BE, O'Quinn S, Trevor J, Carr WW, Belton L, Trudo F, Ambrose CS. Health-Related Quality of Life and Productivity Among US Patients with Severe Asthma. J Asthma Allergy. 2021 Jun 25;14:713-725. doi: 10.2147/JAA.S305513. eCollection 2021.
- Ambrose CS, Chipps BE, Moore WC, Soong W, Trevor J, Ledford DK, Carr WW, Lugogo N, Trudo F, Tran TN, Panettieri RA Jr. The CHRONICLE Study of US Adults with Subspecialist-Treated Severe Asthma: Objectives, Design, and Initial Results. Pragmat Obs Res. 2020 Jul 16;11:77-90. doi: 10.2147/POR.S251120. eCollection 2020.
- Moore WC, Panettieri RA Jr, Trevor J, Ledford DK, Lugogo N, Soong W, Chipps BE, Carr W, Belton L, Gandhi H, Trudo F, Ambrose CS. Biologic and maintenance systemic corticosteroid therapy among US subspecialist-treated patients with severe asthma. Ann Allergy Asthma Immunol. 2020 Sep;125(3):294-303.e1. doi: 10.1016/j.anai.2020.04.004. Epub 2020 Apr 15.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- D3250R00023
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
SingHealth PolyclinicsNot yet recruitingAsthma | Asthma in Children | Asthma Attack | Asthma Acute | Asthma Chronic
-
Johann Wolfgang Goethe University HospitalCompleted
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia